Charles River Laboratories International, Inc.’s stock price dips to $173.91, marking a 2.34% decrease: A Comprehensive Analysis

Charles River Laboratories International, Inc. (CRL)

173.91 USD -4.17 (-2.34%) Volume: 1.21M

Charles River Laboratories International, Inc.’s stock price currently stands at 173.91 USD, marking a -2.34% change in this trading session with a trading volume of 1.21M. The stock has seen a -4.91% change Year-To-Date, reflecting its performance in the market.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories International (NYSE:CRL) has been in the spotlight recently due to a series of events leading up to its stock price movements today. The company’s CEO disclosed a drop in the 2025 revenue outlook at the J.P. Morgan Healthcare Conference, causing the stock to fall 6% on a dim FY25 outlook. Charles River Labs also discussed its 2025 financial outlook, disappointing investors with a damp forecast. Despite seeking strategic acquisitions and presenting a strategic overview at the conference, the stock target was cut with a hold rating on the expected decline. With Charles River Laboratories stock hitting a new 1-year low at $176.34, analysts from JPMorgan and Bank of America have maintained a neutral stance on the stock due to challenges ahead. Citi also flagged revenue and margin headwinds for Charles River Labs shares, while TD Cowen remains cautious as the 2025 guide signals further declines. Overall, the stock has been under pressure as the company grapples with a challenging outlook for the year ahead.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Charles River Laboratories has a positive long-term outlook. The company scores high in growth and momentum, indicating strong potential for future expansion and performance. With a focus on providing research tools and support services for drug discovery and development, Charles River Laboratories is well-positioned to meet the needs of pharmaceutical and biotechnology companies, hospitals, and academic institutions.

However, the company scores lower in terms of dividend and resilience, suggesting that investors may need to consider these factors when evaluating Charles River Laboratories. Overall, with a solid foundation in research models for new drugs and therapies, Charles River Laboratories shows promise for continued success in the industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma